Early-stage Hodgkin's lymphoma

New England Journal of Medicine

Volumn 363, Issue 7, 2010, Pages 653-662

  Armitage, James O ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; EARLY CANCER; GERIATRICS; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT FAILURE; AGE; FEMALE; MULTIMODALITY CANCER THERAPY; PREGNANCY COMPLICATION; PROGNOSIS; RADIATION DOSE; RADIOTHERAPY;

AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROGNOSIS; RADIOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 77956643001     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1003733     Document Type: Review

References (48)

1. Easson EC, Russell MH. Cure of Hodgkin's disease. Br Med J 1963;1:1704-7.
2. Peters MV, Middlemiss KC. A study of Hodgkin's disease treated by irradiation. Am J Roentgenol Radium Ther Nucl Med 1958;79:114-21.
3. Kaplan HS. The radical radiotherapy of regionally localized Hodgkin's disease. Radiology 1962;78:553-61.
4. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1.
5. Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970;73:881-95.
6. Rosenberg SA. Development of the concept of Hodgkin's disease as a curable illness: the American experience. In: Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM, eds. Hodgkin's disease. Philadelphia: Lippincott Williams & Wilkins, 1999:47-57.
7. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004;22:2835-41.
8. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995;13:1080-8.
9. Ziegler JL, Fass L, Bluming AZ, Magrath IT, Templeton AC. Chemotherapy of childhood Hodgkin's disease in Uganda. Lancet 1972;2:679-82.
10. Olweny CL, Katongole-Mbidde E, Kiire C, Lwanga SK, Magrath I, Ziegler JL. Childhood Hodgkin's disease in Uganda: a ten year experience. Cancer 1978;42:787-92.
11. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:32-44.
12. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006;24:3128-35.
13. Canellos GP, Abramson JS, Fisher DC, LaCasce AS. Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol 2010;28:1611-5.
14. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998;339:1506-14.
15. Rueda Domínguez A, Márquez A, Gumá J, et al. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 2004;15:1798-804.
16. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma. J Clin Oncol 2005;23:4634-42.
17. Fermé C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007;357:1916-27.
18. Pavone V, Ricardi U, Luminari S, et al. ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. Ann Oncol 2008;19:763-8.
19. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:3601-8.
20. Borchmann P, Diehl V, Goergen H, et al. Combined modality treatment with intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavourable Hodgkin lymphoma (HL): final analysis of the German Hodgkin Study Group (GHSG) HD11 Trial. Blood 2009;114:299. abstract.
21. Longo DL, Glatstein E, Duffey PL. A prospective trial of radiation alone vs combination chemotherapy alone for early-stage Hodgkin's disease: implications of 25-year follow-up to current combined modality therapy. Blood 2006;108:33a. abstract.
22. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004;104:3483-9.
23. Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006;17:1749-60.
24. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005;97:1428-37.
25. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182-92.
26. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003;95:971-80.
27. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007;99:206-14.
28. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004;22:3139-48.
29. Heidenreich PA, Hancock SL, Vagelos RH, Lee BK, Schnittger I. Diastolic dysfunction after mediastinal irradiation. Am Heart J 2005;150:977-82.
30. De Bruin ML, Dorresteijn LD, van't Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 2009;101:928-37.
31. Swerdlow AJ, Schoemaker MJ, Allerton R, et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol 2001;19:1610-8.
32. Blayney DW, Longo DL, Young RC, et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987;316:710-4.
33. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878-86.
34. Heutte N, Flechtner HH, Mounier N, et al. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol 2009;10:1160-70.
35. Rizack T, Mega A, Legare R, Castillo J. Management of hematological malignancies during pregnancy. Am J Hematol 2009;84:830-41.
36. MacMahon B. Epidemiology of Hodgkin's disease. Cancer Res 1966;26:1189-201.
37. Idem. Epidemiological considerations in staging of Hodgkin's disease. Cancer Res 1971;31:1854-7.
38. Klimm B, Eich HT, Haverkamp H, et al. Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. Ann Oncol 2007;18:357-63.
39. Weekes CD, Vose JM, Lynch JC, et al. Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol 2002;20:1087-93.
40. Evens AM, Sweetenham JW, Horning SJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park) 2008;22:1369-79.
41. Hentrich M, Maretta L, Chow KU, et al. Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol 2006;17:914-9.
42. Swerdlow SH, Campo E, Harris NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: International Agency for Research on Cancer, 2008.
43. Al-Mansour M, Connors JM, Gascoyne RD, Skinnider B, Savage KJ. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol 2010;28:793-9.
44. Chen RC, Chin MS, Ng AK, et al. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol 2010;28:136-41.
45. Ng AK, Li S, Neuberg D, Silver B, Weeks J, Mauch P. Factors influencing treatment recommendations in early-stage Hodgkin's disease: a survey of physicians. Ann Oncol 2004;15:261-9.
46. National Comprehensive Cancer Network. NCCN guidelines & clinical resources. (Accessed July 16, 2010, at http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp.)
47. Sher DJ, Mauch PM, Van Den Abbeele A, LaCasce AS, Czerminski J, Ng AK. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Ann Oncol 2009;20:1848-53.
48. Barnes JA, LaCasce AS, Toomey CE, et al. Early interim FDG-PET scan predicts outcome in non-bulky limited stage Hodgkin lymphoma, but may not guide use of consolidative radiotherapy. Blood 2008;112:518. abstract.